EFFECTS OF SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK IN TOPCAT AMERICAS

被引：0
|
作者：
Chatur, Safia [1 ]
Beldhuis, Iris [1 ]
Neuen, Brendon [1 ]
Claggett, Brian [1 ]
Desai, Akshay S. [1 ]
Lewis, Eldrin F. [1 ]
Anand, Inderjit S. [1 ]
Shah, Sanjiv Jayendra [1 ]
Sweitzer, Nancy K. [1 ]
Fang, James C. [1 ]
Pitt, Bertram [1 ]
Pfeffer, Marc A. [1 ]
Vaduganathan, Muthiah [1 ]
Solomon, Scott D. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1051-07
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [31] Regional Differences in Cardiac Biomarker Profile and Effect of Spironolactone in Patients With Heart Failure and Preserved Ejection Fraction Enrolled in the TOPCAT Trial
    Desai, Akshay
    de Denus, Simon
    Claggett, Brian
    Jarolim, Petr
    Anand, Inder S.
    Fang, James C.
    Moe, Gordon
    Pitt, Bertram
    Pfeffer, Marc A.
    Rouleau, Jean L.
    Solomon, Scott D.
    Sweitzer, Nancy K.
    O'Meara, Eileen
    CIRCULATION, 2016, 134
  • [32] The effects of spironolactone and metoprolol on QT dispersion in patients with congestive heart failure
    Akbulut, M
    Karaca, I
    Ilkay, E
    Özbay, Y
    Arslan, N
    ADVANCES IN CORONARY ARTERY DISEASE, 2001, : 561 - 566
  • [33] Spironolactone in patients with heart failure: friend or foe?
    Khateeb, M.
    Conboy, T.
    Bdeir, M. B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S291 - S291
  • [34] Spironolactone and ventricular arrhythmias in patients with heart failure
    Ramires, FJA
    Mansur, A
    Coelho, O
    Maranhao, M
    Mady, C
    Ramires, JAF
    CIRCULATION, 1998, 98 (17) : 300 - 300
  • [35] The safety of spironolactone treatment in patients with heart failure
    Anton, C
    Cox, AR
    Watson, RDS
    Ferner, RE
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (04) : 285 - 287
  • [36] Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology
    Kosiorek, Aneta
    Biegus, Jan
    Rozentryt, Piotr
    Hurkacz, Magdalena
    Zymlinski, Robert
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 31 (04): : 445 - 455
  • [37] Impact of Spironolactone on Profibrotic Markers in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT)
    O'Meara, Eileen
    de Denus, Simon
    Claggett, Brian L.
    Zile, Michael R.
    Anand, Inder S.
    Shah, Sanjiv J.
    Sirois, Martin G.
    Solomon, Scott D.
    Bertram, Pitt
    Pfeffer, Marc A.
    Rouleau, Jean L.
    Desai, Akshay S.
    CIRCULATION, 2016, 134
  • [38] Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT
    Lin, Yingwen
    Zhao, Hengli
    Hu, Dongtu
    Huang, Jia
    Peng, You
    Li, Juncong
    Xu, Dingli
    Zeng, Qingchun
    CHINESE MEDICAL JOURNAL, 2024, 137 (10) : 1249 - 1251
  • [39] Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT
    Lin Yingwen
    Zhao Hengli
    Hu Dongtu
    Huang Jia
    Peng You
    Li Juncong
    Xu Dingli
    Zeng Qingchun
    中华医学杂志英文版, 2024, 137 (10)
  • [40] Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction A Secondary Analysis of TOPCAT Trial
    Merrill, Miranda
    Sweitzer, Nancy K.
    Lindenfeld, JoAnn
    Kao, David P.
    JACC-HEART FAILURE, 2019, 7 (03) : 228 - 238
12345